Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer
Zhang, Wei, Fan, Yibao, Zhang, Jinze, Shi, Dan, Yuan, Jiahui, Ashrafizadeh, Milad, Li, Wei, Hu, Man, Abd El-Aty, A. M., Hacimuftuoglu, Ahmet, Linnebacher, Michael, Cheng, Yongxian, Li, Weiguang, Fang, Shuo, Gong, Peng, Zhang, Xianbin
Aims: Multidrug resistance in pancreatic cancer poses a significant challenge in clinical treatment. Bufalin (BA), a compound found in secretions from the glands of toads, may help overcome this problem. However, severe cardiotoxicity thus far has hindered its clinical application. Hence, the present study aimed to develop a cell membrane-camouflaged and BA-loaded polylactic-co-glycolic acid nanoparticle (CBAP) and assess its potential to counter chemoresistance in pancreatic cancer.Methods: The toxicity of CBAP was evaluated by electrocardiogram, body weight, distress score, and nesting behavior of mice. In addition, the anticarcinoma activity and underlying mechanism were investigated both in vitro and in vivo.Results: CBAP significantly mitigated BA-mediated acute cardiotoxicity and enhanced the sensitivity of pancreatic cancer to several clinical drugs, such as gemcitabine, 5-fluorouracil, and FOLFIRINOX. Mechanistically, CBAP directly bound to nucleotide-binding and oligomerization domain containing protein 2 (NOD2) and inhibited the expression of nuclear factor kappa-light-chain-enhancer of activated B cells. This inhibits the expression of ATP -binding cassette transporters, which are responsible for chemoresistance in cancer cells.Conclusions: Our findings indicate that CBAP directly inhibits NOD2. Combining CBAP with standard-of-care chemotherapeutics represents a safe and efficient strategy for the treatment of pancreatic cancer.
- Dergi
- DRUG RESISTANCE UPDATES
- Yıl
- 2023
- Cilt
- 71
- ISSN
- 1368-7646
- eISSN
- 1532-2084
- DOI
- 10.1016/j.drup.2023.101005
- WoS UID
- WOS:001071578400001